Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy

Volume: 62, Issue: 4, Pages: 956 - 967
Published: Apr 1, 2015
Abstract
In the treatment of chronic hepatitis B (CHB), the ultimate goal is preventing hepatitis B virus (HBV)-associated liver disease, including hepatocellular carcinoma (HCC). Recently published studies show that in CHB patients treated with the currently recommended first-line nucleos(t)ide analogs (NAs) entecavir or tenofovir, annual HCC incidences range from 0.01% to 1.4% in non-cirrhotic patients, and from 0.9% to 5.4% in those with cirrhosis. In...
Paper Details
Title
Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy
Published Date
Apr 1, 2015
Volume
62
Issue
4
Pages
956 - 967
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.